Alzheimer’s disease affects over 55 million people globally, including nearly 10 million in China. The disease imposes an average annual direct medical cost exceeding 120,000 RMB per patient, increases family care expenses by 63%, and causes moderate-to-severe cognitive impairment in 55% of cases. Conventional drug therapies merely slow progression and lack efficacy against abnormal amyloid-beta (Aβ) brain deposits. The Department of Neurosurgery pioneered Chongqing’s first cervical lymphatic-venous anastomosis, establishing microsurgical connections between lymphatic vessels (0.3–0.8 mm) and veins to accelerate cerebrospinal lymphatic drainage and enhance metabolic waste clearance. To date, 50 procedures have been performed, achieving an overall efficacy rate over 90%. This technique is internationally recognized as a leading innovation, offering new hope to millions of Alzheimer’s patients worldwide.